Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0247-0829 Phase 1 in Overweight or Obesity
NCT04010786Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Jul 2019
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Overweight and obesity comparing Active treatment NNC0247-0829 with Placebo (2 arms). Primary endpoint: Number of treatment emergent adverse events. Started Jul 2019; status: completed.
02
Drugs
NNC0247-0829
03
Conditions
Overweightobesity
Beyond the preview
Go deeper on NCT04010786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04010786.